Previous Close
Price To Book
Market Cap 0
Shares 0
Volume 0
Short Ratio
Av. Daily Volume 0

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data likely due 2Q 2019
Refractory childhood absence epilepsy
Approved January 5, 2012.
Cancer pain
Phase 2 initiated August 2016
Pharmaceutical Cannabidiol (CBD)
Cocaine dependence
Announced approval July 5, 2016.
Dronabinol Oral Solution
AIDS-related anorexia
CRL issued July 27, 2018.
Moderate to severe postoperative pain after bunionectomy
NDA filing likely due 2Q 2019 following data from nonclinical juvenile toxicity trial.
Naloxone nasal spray
Opioid overdose
Phase 2 data due 2H 2019.
Prader-Willi syndrome

Latest News

  1. Opinion: Medical Marijuana Is a Terrible Investment
  2. Insys Therapeutics Bankruptcy: INSY Stock Soars on Latest News
  3. Zynerba Up on Second Patent for Cannabidiol Candidate in 2019
  4. Biotech Stock Roundup: Celgene Submits MS Drug to FDA, INSY & CBAY Crash
  5. Insys Therapeutics' stock jumps after bankruptcy court approves 'First Day' motions
  6. INSYS Therapeutics, Inc. Receives Court Approval of “First Day” Motions
  7. Insys Down on Bankruptcy News Amid Increasing Legal Expenses
  8. Investors are pinning hopes on this asset again — but beware, says Saxo Bank
  9. Chandler opioid maker files for bankruptcy protection
  10. Top Trending: Insys files for bankruptcy, Hudson's Bay offers to go private and more
  11. Insys Therapeutics Bankruptcy: INSY Stock Plunges on the News
  12. Top Marijuana Stocks on the NASDAQ
  13. Insys Files for Bankruptcy, Overwhelmed by Costs of Opioid Suits
  14. Insys Therapeutics Sinks After Filing for Bankruptcy
  15. Insys files for bankruptcy, stock plunges toward record low
  16. Opioid manufacturer Insys files for bankruptcy after kickback probe
  17. UPDATE 4-Opioid manufacturer Insys files for bankruptcy after kickback probe
  18. INSYS Therapeutics Initiates Court-Supervised Process to Facilitate Asset Sales and Address Legacy Liabilities
  19. 3 Marijuana Stocks I Wouldn't Touch With a 10-Foot Pole Right Now